Novo Nordisk CEO Mike Doustdar Talks Drug Sales
Bloomberg Talks
00:00
Bidding Strategy and Deal Dynamics
Guy questions whether Pfizer's interest matters and if Novo would pay more; Doustdar describes assessing Matzero's value and responding to shareholder pricing.
Play episode from 04:28
Transcript
